Verification of suppressing effects of Japanese cedar pollen peptide-containing rice on symptoms and IgE associated with Japanese cedar pollinosis (Study 2)

Verification of suppressing effects of Japanese cedar pollen peptide-containing rice on symptoms and IgE associated with Japanese cedar pollinosis (Study 2) - Verification of suppressing effect of Japanese cedar pollen peptide-containing rice on Japanese cedar pollen-specific IgE

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024700

Enrollment

Registered

2016-11-04

Start date

2016-09-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Japanese cedar pollinosis

Interventions

Japanese cedar pollen allergy relief rice 5g intake group (allergy rerief rice 5g plus pracebo rice 45g once a day, for 96 weeks, 10 cases)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)those who have presented with symptoms related allergic rhinitis such as sneezing, nasal discharge, obstruction and eye itching for at least 2continuous years, consistent with the cedar pollen season 2)those whose Japanese cedar pollen allergen-specific IgE antibody titer show class the 2 or more (measured by AlaSTAT 3g method) 3)those whose Japanese cypress pollen-specific IgE antibody titer show the class 4 or less (AlaSTAT 3g) 4)those who live or work in Osaka prefecture and consented to research participation by the document from the person obtained 5)those who can comply with not to transfer the test product to a third party

Exclusion criteria

Exclusion criteria: 1)those whom Principal Investigator or the sharing researchers have determined inappropriate 2)those who suffer from rice allergy or have a history of rice allergy 3)those whose pets (dogs, cats) and house dust and mite-specific IgE antibody titers show the class of 5 or more, ond who are breeding a pet. 4)those whose house dust and mite-specific IgE antibody titer, swow higher than the cedar pollen-specific IgE antibody titers 5)those who have received immunotherapy for cedar pollen, or have the schedule 6)those who suffer from some serious disease with disease activity, therefore, are judged unsuitable for enrolement by the clinician 7)those who are or planning to become pregnant or in the process of breast-feeding during the clinical reseach 8)those who are participating in other clinical research

Design outcomes

Primary

Measure	Time frame
serum Japanese cedar pollen-specific IgE antibody level at 0, 12, 24, 36 48, 60, 72, 84, 96weeks after the stat of ingestion	—

Secondary

Measure	Time frame
1)Japanese cedar pollen-specific T cell proliferative response at at 0, 12, 24, 36 48, 60, 72, 84, 96weeks after the stat of ingestion 2)Adverse events from the start to the end of ingestion	—

Countries

Japan

Contacts

Public ContactShoji Hashimoto

Osaka Habikino Medical Center Clinical Reseach Center

hashisyo@ra.opho.jp072-957-2121

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026